[
  {
    "ts": null,
    "headline": "Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising.",
    "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
    "url": "https://finnhub.io/api/news?id=e023ba7adf30612f58aff2384b5aca279f281f7299d45492b80c82e255d58123",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770316140,
      "headline": "Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising.",
      "id": 138367495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
      "url": "https://finnhub.io/api/news?id=e023ba7adf30612f58aff2384b5aca279f281f7299d45492b80c82e255d58123"
    }
  },
  {
    "ts": null,
    "headline": "Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game",
    "summary": "Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.",
    "url": "https://finnhub.io/api/news?id=45bf1f51a16434d720f80c7fb6d1f0bb4c047c54b4d6ef26bc4597375ef87d3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770309120,
      "headline": "Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game",
      "id": 138368710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.",
      "url": "https://finnhub.io/api/news?id=45bf1f51a16434d720f80c7fb6d1f0bb4c047c54b4d6ef26bc4597375ef87d3e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag.",
    "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
    "url": "https://finnhub.io/api/news?id=97db74ad7b72973be06edf50945817c5cee783d8b3cbd76b135d1ae7ee095c5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305100,
      "headline": "Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag.",
      "id": 138366087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.",
      "url": "https://finnhub.io/api/news?id=97db74ad7b72973be06edf50945817c5cee783d8b3cbd76b135d1ae7ee095c5b"
    }
  },
  {
    "ts": null,
    "headline": "Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results",
    "summary": "Stock futures are mixed and have shown modest signs of stabilization after a sharp downturn in software and AI-related technology stocks yesterday, prompting some investors to treat the technology selloff that pressured equities broadly as a buying opportunity. Against that backdrop, defensive sectors and commodity-linked assets have drawn interest, particularly as gold reclaimed levels above $5,000 an ounce, reflecting continued demand for safe havens amid uncertainty. Claim 50% Off TipRanks Pr",
    "url": "https://finnhub.io/api/news?id=cfaad9cb9c8162fc497e630737dd9f08ad8a09c9963d03c6eb09d779786d0bd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300052,
      "headline": "Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results",
      "id": 138363701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Stock futures are mixed and have shown modest signs of stabilization after a sharp downturn in software and AI-related technology stocks yesterday, prompting some investors to treat the technology selloff that pressured equities broadly as a buying opportunity. Against that backdrop, defensive sectors and commodity-linked assets have drawn interest, particularly as gold reclaimed levels above $5,000 an ounce, reflecting continued demand for safe havens amid uncertainty. Claim 50% Off TipRanks Pr",
      "url": "https://finnhub.io/api/news?id=cfaad9cb9c8162fc497e630737dd9f08ad8a09c9963d03c6eb09d779786d0bd9"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=bdde54aa64e682c2e876dfac427a5b13dd23c1764bd5a19711cc82c085c3e5ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300003,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 138366088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=bdde54aa64e682c2e876dfac427a5b13dd23c1764bd5a19711cc82c085c3e5ff"
    }
  },
  {
    "ts": null,
    "headline": "Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?",
    "summary": "IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.",
    "url": "https://finnhub.io/api/news?id=9c238726da7e950692b84b8ff07073cda44d3becb6534fbeeb6aad23f99e634f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770299280,
      "headline": "Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?",
      "id": 138364469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.",
      "url": "https://finnhub.io/api/news?id=9c238726da7e950692b84b8ff07073cda44d3becb6534fbeeb6aad23f99e634f"
    }
  },
  {
    "ts": null,
    "headline": "Rapid Innovation is Reshaping Oncology: Stocks in Focus",
    "summary": "Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.",
    "url": "https://finnhub.io/api/news?id=84a1adc6e1efe18c2f819891107581848711335376a33f54f0b7fb21a9f23772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296280,
      "headline": "Rapid Innovation is Reshaping Oncology: Stocks in Focus",
      "id": 138364449,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.",
      "url": "https://finnhub.io/api/news?id=84a1adc6e1efe18c2f819891107581848711335376a33f54f0b7fb21a9f23772"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: The Market Is Getting It Wrong",
    "summary": "AbbVie reports 10% revenue growth, 25% EPS gains, 360 bps margin expansion, and a 14.81x forward P/E with $14.57 EPS guidance. See why ABBV stock is a buy.",
    "url": "https://finnhub.io/api/news?id=2ac921b13867384221922c940808a781321d249c7c2c7752a2ead9ff43ac29e0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770281527,
      "headline": "AbbVie: The Market Is Getting It Wrong",
      "id": 138363678,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie reports 10% revenue growth, 25% EPS gains, 360 bps margin expansion, and a 14.81x forward P/E with $14.57 EPS guidance. See why ABBV stock is a buy.",
      "url": "https://finnhub.io/api/news?id=2ac921b13867384221922c940808a781321d249c7c2c7752a2ead9ff43ac29e0"
    }
  },
  {
    "ts": null,
    "headline": "ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 6% year on year to $16 billion. Its non-GAAP profit of $2.71 per share was 2.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=1cdf3a0661796965dd59c06a135735e7d38f69e697448af3db6640821b0e8262",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770269565,
      "headline": "ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds",
      "id": 138362681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 6% year on year to $16 billion. Its non-GAAP profit of $2.71 per share was 2.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=1cdf3a0661796965dd59c06a135735e7d38f69e697448af3db6640821b0e8262"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot",
    "summary": "AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions. Check out why ABBV stock is a buy.",
    "url": "https://finnhub.io/api/news?id=2d95169f264fd464199e1f1364e4082d06de9044e87f2eb38b25c70241d1f83d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770265507,
      "headline": "AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot",
      "id": 138361942,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186297809/image_2186297809.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions. Check out why ABBV stock is a buy.",
      "url": "https://finnhub.io/api/news?id=2d95169f264fd464199e1f1364e4082d06de9044e87f2eb38b25c70241d1f83d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Q4 Earnings Call Highlights",
    "summary": "AbbVie (NYSE:ABBV) executives said the company closed 2025 with record revenue and earnings above initial expectations, citing strong performance from its “ex-Humira growth platform,” continued momentum for Skyrizi and Rinvoq, and expanding contributions from neuroscience and other franchises. On t",
    "url": "https://finnhub.io/api/news?id=de425540ae6eaf5932337289246b651a5eb8a5bd18da802717d557f1dbb1e1f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770260915,
      "headline": "AbbVie Q4 Earnings Call Highlights",
      "id": 138360516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) executives said the company closed 2025 with record revenue and earnings above initial expectations, citing strong performance from its “ex-Humira growth platform,” continued momentum for Skyrizi and Rinvoq, and expanding contributions from neuroscience and other franchises. On t",
      "url": "https://finnhub.io/api/news?id=de425540ae6eaf5932337289246b651a5eb8a5bd18da802717d557f1dbb1e1f2"
    }
  }
]